Compare Intel Corp (INTC) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intel Corp vs Smith & Nephew plc — how do they compare? Intel Corp trades at $105.69 (market cap $566.04B), while Smith & Nephew plc trades at $27.14 (market cap $11.10B). The key difference: Intel Corp is far larger — about 51× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Intel Corp for 116 Days and Smith & Nephew plc for 120 Days on average.
| INTC | SNN | |
|---|---|---|
Market Cap | $566.04B | $11.10B |
Volume | 118,475,837 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $140.94 | $37.17 |
52-Week Low | $33.62 | $26.42 |
Typical Hold Time | 116 Days | 120 Days |
Enterprise Value | $586.85B | $14.13B |
Dividend Yield | 2.24% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intel (INTC) trades at $105.75, down 6.52% over the past 24 hours, with a mixed technical picture showing bullish overall signals but bearish moving averages and oscillators. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.42 beating expectations of $0.21. However, Intel faces fundamental challenges with negative net income margins (-19.79%) and elevated valuation ratios (P/E of 904.17), though operating cash flow improved to $9.7 billion in 2025.
Intel's turnaround story shows early signs of progress with strong foundry revenue growth and government support, but profitability remains a concern. The stock offers potential upside to the analyst consensus price target of $111.72, though execution risks in the competitive semiconductor space and high debt levels pose significant challenges for investors seeking sustained recovery.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
